Literature DB >> 2207320

Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia.

C H Pui1, W M Crist, A T Look.   

Abstract

Virtually all cases of childhood ALL have chromosomal abnormalities and half contain translocations, which are nearly equally divided between random and nonrandom rearrangements. Nonrandom chromosomal abnormalities have been correlated with leukemic cell lineage, the degree of cell differentiation, and the specific gene involved at the molecular level. Many cytogenetic findings have prognostic significance; however, the adverse influence of certain changes, including most chromosomal translocations, may in fact be offset by the greater cytoreductive effects of intensified therapy. Table 4 summarizes the relation of selected karyotypic findings to treatment outcome in patients treated on contemporary protocols. Among all of the chromosomal abnormalities identified in childhood ALL, hyperdiploidy greater than 50 has been associated with the most favorable prognosis. At the opposite end of the spectrum, the treatment outcome for patients with classical Ph+ or hypodiploid ALL is very poor even in programs of intensive chemotherapy; alternative treatment such as bone marrow transplantation should be considered for such patients. Cases with the t(4;11)(q21;q23) also have a very poor clinical outcome, but the adverse prognosis may be limited to the infant or adolescent age groups. The prognostic significance of other nonrandom translocations, such as t(1;19)(q23;p13) and several other abnormalities, needs to be further assessed in larger numbers of patients. Finally, as more is learned about the molecular pathology underlying these rearrangements, it may be possible to develop new therapeutic agents that are specifically targeted to interfere with the aberrant gene products expressed by human leukemic cells.

Entities:  

Mesh:

Year:  1990        PMID: 2207320

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  The study of minimal residual disease in acute lymphoblastic leukaemia.

Authors:  C J Knechtli; N J Goulden; K Langlands; M N Potter
Journal:  Clin Mol Pathol       Date:  1995-04

Review 2.  Early embryonal/fetal lymphopoietic ontogeny and leukemogenesis.

Authors:  G Prindull
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

Review 3.  Diagnostic molecular techniques in haematology: recent advances.

Authors:  Aikaterini Koutsi; Elisavet-Christina Vervesou
Journal:  Ann Transl Med       Date:  2018-06

Review 4.  Pharmacogenomics in the clinic.

Authors:  Mary V Relling; William E Evans
Journal:  Nature       Date:  2015-10-15       Impact factor: 49.962

5.  Immunogenetics and the aetiology of childhood leukaemia.

Authors:  G M Taylor
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

Review 6.  Factors in improved survival from paediatric cancer.

Authors:  J W Taub
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

7.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

8.  Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia.

Authors:  Faith Galderisi; Linda Stork; Ju Li; Motomi Mori; Solange Mongoue-Tchokote; James Huang
Journal:  Pediatr Blood Cancer       Date:  2009-10       Impact factor: 3.167

9.  A unique complex translocation involving six different chromosomes in a case of childhood acute lymphoblastic leukemia with the Philadelphia chromosome and adverse prognosis.

Authors:  Walid Al Achkar; Abdulsamad Wafa; Hasmik Mkrtchyan; Faten Moassass; Thomas Liehr
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

10.  Chemotherapy versus bone marrow transplantation in childhood acute lymphoblastic leukaemia. BFM Study Group.

Authors:  W Ebell; A Reiter; H Riehm
Journal:  Eur J Pediatr       Date:  1992       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.